SeaBeLife: SeaBeLife secures 1.2M to develop drug candidates intended to block cell necrosis
French biotech firm SeaBeLife has raised €1.2 million in additional seed funding to fund the further development of its drug candidates for acute liver disease and eye disorders as well as allow it to...
Read full article »
SeaBeLife is a France-based biotechnology company that researches and develops small molecules for the treatment of regulated necrosis.
Read more